200,000+ products from a single source!
sales@angenechem.com
Home > Pyridines > 192329-42-3
192329-42-3 | 3-Thiomorpholinecarboxamide, N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-, (3S)-
CAS No: 192329-42-3 Catalog No: AG002FUQ MDL No:
Product Description
Catalog Number:
AG002FUQ
Chemical Name:
3-Thiomorpholinecarboxamide, N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-, (3S)-
CAS Number:
192329-42-3
Molecular Formula:
C18H21N3O5S2
Molecular Weight:
423.5064
IUPAC Name:
(3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide
InChI:
InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1
InChI Key:
YKPYIPVDTNNYCN-INIZCTEOSA-N
SMILES:
ONC(=O)[C@@H]1N(CCSC1(C)C)S(=O)(=O)c1ccc(cc1)Oc1ccncc1
UNII:
10T6626FRK
Properties
Complexity:
638
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
0
Exact Mass:
423.092g/mol
Formal Charge:
0
Heavy Atom Count:
28
Hydrogen Bond Acceptor Count:
8
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
423.502g/mol
Monoisotopic Mass:
423.092g/mol
Rotatable Bond Count:
5
Topological Polar Surface Area:
143A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.5
Literature
| Title | Journal |
|---|---|
| Crystal structure of human cytochrome P450 2D6 with prinomastat bound. | The Journal of biological chemistry 20120330 |
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | Journal of medicinal chemistry 20110714 |
| A high throughput screen identifies chemical modulators of the laminin-induced clustering of dystroglycan and aquaporin-4 in primary astrocytes. | PloS one 20110101 |
| Hydroxamates: relationships between structure and plasma stability. | Journal of medicinal chemistry 20091112 |
| Inhibition of gelatinase activity reduces neural injury in an ex vivo model of hypoxia-ischemia. | Neuroscience 20090602 |
| Current perspective of TACE inhibitors: a review. | Bioorganic & medicinal chemistry 20090115 |
| Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat. | Journal of neuroinflammation 20080101 |
| Specific inhibition of autoimmune T cell transmigration contributes to beta cell functionality and insulin synthesis in non-obese diabetic (NOD) mice. | The Journal of biological chemistry 20071102 |
| Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators. | Toxicon : official journal of the International Society on Toxinology 20070401 |
| Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases. | Bioorganic & medicinal chemistry 20070315 |
| Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR. | Investigative ophthalmology & visual science 20070201 |
| Rapid vascular regrowth in tumors after reversal of VEGF inhibition. | The Journal of clinical investigation 20061002 |
| Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. | Bioorganic & medicinal chemistry 20060615 |
| Cyclic mechanical strain-induced proliferation and migration of human airway smooth muscle cells: role of EMMPRIN and MMPs. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050901 |
| Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201 |
| Protease inhibitors in the clinic. | Medicinal chemistry (Shariqah (United Arab Emirates)) 20050101 |
| Cartilage degradation independent of MMP/aggrecanases. | Osteoarthritis and cartilage 20041201 |
| The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinase, on a new animal model of epiretinal membrane. | Retina (Philadelphia, Pa.) 20041001 |
| Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20040601 |
| Receptor flexibility in the in silico screening of reagents in the S1' pocket of human collagenase. | Journal of medicinal chemistry 20040520 |
| The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. | Cancer research 20040401 |
| Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11. | Journal of medicinal chemistry 20040115 |
| Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors. | Journal of medicinal chemistry 20030828 |
| Prinomastat, a hydroxamate inhibitor of matrix metalloproteinases, has a complex effect on migration of breast carcinoma cells. | International journal of cancer 20030501 |
| Mechanical stretch induces MMP-2 release and activation in lung endothelium: role of EMMPRIN. | American journal of physiology. Lung cellular and molecular physiology 20030301 |
| [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects]. | Annales de biologie clinique 20030101 |
| Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions. | Bioorganic & medicinal chemistry letters 20021007 |
| Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. | The Journal of biological chemistry 20020322 |
| Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. | Journal of medicinal chemistry 20020103 |
| Efficacy of Prinomastat) (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. | Current eye research 20020101 |
| Imaging metalloproteinase activity in vivo. | Nature medicine 20010601 |
| Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20010601 |
| Development of matrix metalloproteinase inhibitors in cancer therapy. | Journal of the National Cancer Institute 20010207 |
| HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. | Annals of neurology 20010201 |
| The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. | Ophthalmic research 20010101 |
| Therapeutic angiogenesis inhibitors in the treatment of cancer. | Advances in internal medicine 20010101 |
| Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. | Expert opinion on investigational drugs 20000901 |
| Protease inhibitors: current status and future prospects. | Journal of medicinal chemistry 20000210 |
| Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. | Annals of the New York Academy of Sciences 19990630 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.